{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:36:59Z","timestamp":1781073419409,"version":"3.54.1"},"reference-count":71,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["bmn.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Discovery Today"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.drudis.2021.06.010","type":"journal-article","created":{"date-parts":[[2021,7,2]],"date-time":"2021-07-02T23:48:17Z","timestamp":1625269697000},"page":"2465-2473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["IFN-\u03b1: A key therapeutic target for multiple autoimmune rheumatic diseases"],"prefix":"10.1016","volume":"26","author":[{"given":"Fr\u00e9d\u00e9ric","family":"De Ceuninck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Duguet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3432-6223","authenticated-orcid":false,"given":"Audrey","family":"Aussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Laigle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2380-9983","authenticated-orcid":false,"given":"Philippe","family":"Moingeon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.drudis.2021.06.010_b0005","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nrd2422","article-title":"Interferons at age 50: past, current and future impact on biomedicine","volume":"6","author":"Borden","year":"2007","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2021.06.010_b0010","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1038\/nrrheum.2018.31","article-title":"Type I interferon in rheumatic diseases","volume":"14","author":"Muskardin","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0015","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.606456","article-title":"Type I interferon (IFN)-regulated activation of canonical and non-canonical signaling pathways","volume":"11","author":"Mazewski","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.drudis.2021.06.010_b0020","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1089\/jir.2011.0071","article-title":"Interferon alpha as a primary pathogenic factor in human lupus","volume":"31","author":"Niewold","year":"2011","journal-title":"J Interferon Cytokine Res"},{"issue":"Suppl. 118","key":"10.1016\/j.drudis.2021.06.010_b0025","first-page":"185","article-title":"Type I interferon signature in Sjogren\u2019s syndrome: pathophysiological and clinical implications","volume":"37","author":"Marketos","year":"2019","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2018.12.018","article-title":"Type I interferon dysregulation in systemic sclerosis","volume":"132","author":"Skaug","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.drudis.2021.06.010_b0035","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1093\/rheumatology\/ket413","article-title":"Suppression of soluble T cell-associated proteins by an anti-interferon-\u03b1 monoclonal antibody in adult patients with dermatomyositis or polymyositis","volume":"53","author":"Guo","year":"2014","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.drudis.2021.06.010_b0040","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(13)61499-3","article-title":"Clinical aspects of autoimmune rheumatic diseases","volume":"382","author":"Goldblatt","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.drudis.2021.06.010_b0045","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1038\/s41573-020-00092-2","article-title":"B cell depletion therapies in autoimmune disease: advances and mechanistic insights","volume":"20","author":"Lee","year":"2021","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2021.06.010_b0050","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/nrd3436","article-title":"Belimumab","volume":"10","author":"Sanz","year":"2011","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.drudis.2021.06.010_b0055","doi-asserted-by":"crossref","first-page":"5772","DOI":"10.4049\/jimmunol.1401541","article-title":"The plasmacytoid dendritic cell as the Swiss army knife of the immune system: molecular regulation of its multifaceted functions","volume":"193","author":"Karrich","year":"2014","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.06.010_b0060","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1084\/jem.20161451","article-title":"Detection of interferon alpha protein reveals differential levels and cellular sources in disease","volume":"214","author":"Rodero","year":"2017","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2021.06.010_b0065","doi-asserted-by":"crossref","first-page":"6149","DOI":"10.1038\/s41467-020-19918-z","article-title":"Functionally impaired plasmacytoid dendritic cells and non-haematopoietic sources of type I interferon characterize human autoimmunity","volume":"11","author":"Psarras","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2021.06.010_b0070","doi-asserted-by":"crossref","first-page":"4578","DOI":"10.4049\/jimmunol.1501157","article-title":"Cutting edge: plasmacytoid dendritic cells in late-stage lupus mice defective in producing IFN-\u03b1","volume":"195","author":"Liao","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.06.010_b0075","first-page":"1662","article-title":"Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy","volume":"56","author":"Psarras","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.drudis.2021.06.010_b0080","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1038\/cmi.2017.136","article-title":"Extracellular DNA and autoimmune diseases","volume":"15","author":"Lou","year":"2018","journal-title":"Cell Mol Immunol"},{"key":"10.1016\/j.drudis.2021.06.010_b0085","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/BF02826219","article-title":"Dermatomyositis after interferon alpha treatment","volume":"17","author":"Dietrich","year":"2000","journal-title":"Med Oncol"},{"key":"10.1016\/j.drudis.2021.06.010_b0090","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1177\/0961203309353172","article-title":"Systemic lupus erythematosus and Sj\u00f6gren\u2019s syndrome induced in a case by interferon-alpha used for the treatment of hepatitis C","volume":"19","author":"Onishi","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.drudis.2021.06.010_b0095","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1002\/art.30087","article-title":"Interferon-\u03b1 accelerates murine systemic lupus erythematosus in a T cell-dependent manner","volume":"63","author":"Liu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0100","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1084\/jem.20021996","article-title":"Type-I interferon receptor deficiency reduces lupus-like disease in NZB mice","volume":"197","author":"Santiago-Raber","year":"2003","journal-title":"J Exp Med"},{"key":"10.1016\/j.drudis.2021.06.010_b0105","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1002\/1529-0131(199902)42:2<299::AID-ANR12>3.0.CO;2-R","article-title":"Interferon-\u03b1 does not improve outcome at one year in patients with diffuse cutaneous scleroderma: results of a randomized, double-blind, placebo-controlled trial","volume":"42","author":"Black","year":"1999","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0110","doi-asserted-by":"crossref","first-page":"2610","DOI":"10.1073\/pnas.0337679100","article-title":"Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus","volume":"100","author":"Baechler","year":"2003","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.drudis.2021.06.010_b0115","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/08916930310001625952","article-title":"Microarray analysis of interferon-regulated genes in SLE","volume":"36","author":"Crow","year":"2003","journal-title":"Autoimmunity"},{"key":"10.1016\/j.drudis.2021.06.010_b0120","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1136\/ard.2011.150326","article-title":"Patients with systemic lupus erythematosus, myositis, rheumatoid arthritis and scleroderma share activation of a common type I interferon pathway","volume":"70","author":"Higgs","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0125","doi-asserted-by":"crossref","first-page":"2951","DOI":"10.1002\/art.22044","article-title":"Association of increased interferon-inducible gene expression with disease activity and lupus nephritis in patients with systemic lupus erythematosus","volume":"54","author":"Feng","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0130","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.gene.2018.05.041","article-title":"The genetics and molecular pathogenesis of systemic lupus erythematosus (SLE) in populations of different ancestry","volume":"668","author":"Goulielmos","year":"2018","journal-title":"Gene"},{"key":"10.1016\/j.drudis.2021.06.010_b0135","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1093\/rheumatology\/key330","article-title":"Genetics and epigenetics in primary Sj\u00f6gren\u2019s syndrome","volume":"60","author":"Imgenberg-Kreuz","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.drudis.2021.06.010_b0140","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1038\/s41584-018-0099-0","article-title":"New insights into the genetics and epigenetics of systemic sclerosis","volume":"14","author":"Angiolilli","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0145","article-title":"Development and validation of an ultrasensitive single molecule array digital enzyme-linked immunosorbent assay for human interferon-\u03b1","volume":"136","author":"Llibre","year":"2018","journal-title":"J Vis Exp"},{"key":"10.1016\/j.drudis.2021.06.010_b0150","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1002\/art.21890","article-title":"Functional assay of type I Interferon in systemic lupus erythematosus plasma and association with anti-RNA binding protein autoantibodies","volume":"54","author":"Hua","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0155","doi-asserted-by":"crossref","first-page":"2407","DOI":"10.1002\/art.30399","article-title":"Association of endogenous anti-interferon-\u03b1 autoantibodies with decreased interferon-pathway and disease activity in patients with systemic lupus erythematosus","volume":"63","author":"Morimoto","year":"2011","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0160","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40169-018-0218-1","article-title":"Clinical features of Sj\u00f6gren\u2019s syndrome patients with autoantibodies against interferon","volume":"8","author":"Burbelo","year":"2019","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.drudis.2021.06.010_b0165","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1136\/annrheumdis-2012-eular.3140","article-title":"Results of a randomized placebo controlled phase 1a study of AGS-009, a humanized anti-interferon-\u03b1 monoclonal antibody in subjects with systemic lupus erythematosus","volume":"71","author":"Tcherepanova","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0170","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1136\/ard.2010.144485","article-title":"Safety profile and clinical activity of sifalimumab, a fully human anti-interferon \u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study","volume":"70","author":"Merrill","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0175","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1002\/art.37824","article-title":"Sifalimumab, a human anti-interferon-\u03b1 monoclonal antibody, in systemic lupus erythematosus: a phase I randomized, controlled, dose-escalation study","volume":"65","author":"Petri","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0180","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1136\/annrheumdis-2012-202794","article-title":"A phase 1b clinical trial evaluating sifalimumab, an anti-IFN-\u03b1 monoclonal antibody, shows target neutralisation of a type I IFN signature in blood of dermatomyositis and polymyositis patients","volume":"73","author":"Higgs","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0185","doi-asserted-by":"crossref","first-page":"1909","DOI":"10.1136\/annrheumdis-2015-208562","article-title":"Sifalimumab, an anti-interferon-\u03b1 monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study","volume":"75","author":"Khamashta","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0190","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/art.34632","article-title":"Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study","volume":"64","author":"Mc Bride","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0195","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1136\/annrheumdis-2014-206090","article-title":"A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-\u03b1) in patients with systemic lupus erythematosus (ROSE)","volume":"75","author":"Kalunian","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0200","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.cell.2016.06.024","article-title":"AIRE-deficient patients harbor unique high-affinity disease-ameliorating autoantibodies","volume":"166","author":"Meyer","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.drudis.2021.06.010_b0205","article-title":"S95021, a novel selective and pan-neutralizing anti interferon alpha (IFN-\u03b1) monoclonal antibody as a candidate treatment for selected autoimmune rheumatic diseases","volume":"4","author":"Duguet","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.drudis.2021.06.010_b0210","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1016\/S2665-9913(20)30223-X","article-title":"First-in-human study of JNJ-55920839 in healthy volunteers and patients with systemic lupus erythematosus: a randomised placebo-controlled phase 1 trial","volume":"2","author":"Jordan","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0215","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1002\/art.37785","article-title":"Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon \u03b1-kinoid","volume":"65","author":"Lauwerys","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0220","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1136\/annrheumdis-2019-216379","article-title":"IFN-\u03b1 kinoid in systemic lupus erythematosus: results from a phase IIb, randomised, placebo-controlled study","volume":"79","author":"Houssiau","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0225","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.39962","article-title":"Anifrolumab, an anti-interferon-alpha receptor monoclonal antibody, in moderate to severe SLE","volume":"69","author":"Furie","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0230","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/14397595.2020.1812201","article-title":"Anifrolumab, a monoclonal antibody to the type I interferon receptor subunit 1, for the treatment of systemic lupus erythematosus: an overview from clinical trials","volume":"31","author":"Tanaka","year":"2021","journal-title":"Mod Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0235","doi-asserted-by":"crossref","first-page":"14253","DOI":"10.1038\/ncomms14253","article-title":"Natural amines inhibit activation of human plasmacytoid dendritic cells through CXCR4 engagement","volume":"8","author":"Smith","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.drudis.2021.06.010_b0240","doi-asserted-by":"crossref","first-page":"eaav9019","DOI":"10.1126\/sciadv.aav9019","article-title":"Control of TLR7-mediated type I IFN signaling in pDCs through CXCR4 engagement- A new target for lupus treatment","volume":"5","author":"Smith","year":"2019","journal-title":"Sci Adv"},{"key":"10.1016\/j.drudis.2021.06.010_b0245","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1124\/jpet.120.000275","article-title":"Discovery of M5049: a novel selective toll-like receptor 7\/8 inhibitor for the treatment of autoimmunity","volume":"376","author":"Vlach","year":"2021","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.drudis.2021.06.010_b0250","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/bs.ircmb.2018.10.002","article-title":"Cytosolic nucleic acid sensors in inflammatory and autoimmune disorders","volume":"344","author":"Khan","year":"2019","journal-title":"Int Rev Cell Mol Biol"},{"key":"10.1016\/j.drudis.2021.06.010_b0255","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.virol.2005.09.024","article-title":"The interferon response circuit: Induction and suppression by pathogenic viruses","volume":"344","author":"Haller","year":"2006","journal-title":"Virology"},{"key":"10.1016\/j.drudis.2021.06.010_b0260","doi-asserted-by":"crossref","first-page":"5516","DOI":"10.1172\/JCI79100","article-title":"Inherited STING-activating mutation underlies a familial inflammatory syndrome with lupus-like manifestations","volume":"124","author":"Jeremiah","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.drudis.2021.06.010_b0265","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.4049\/jimmunol.1100857","article-title":"Autoimmune disease risk variant of IFIH1 is associated with increased sensitivity to IFN-\u03b1 and serologic autoimmunity in lupus patients","volume":"187","author":"Robinson","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.06.010_b0270","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1002\/art.40002","article-title":"Expression of cyclic GMP-AMP synthase in patients with systemic lupus erythematosus","volume":"69","author":"An","year":"2017","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0275","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1136\/annrheumdis-2018-212988","article-title":"Apoptosis-derived membrane vesicles drive the cGAS\u2013STING pathway and enhance type I IFN production in systemic lupus erythematosus","volume":"77","author":"Kato","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0280","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1016\/j.apsb.2020.03.001","article-title":"Small molecules targeting the innate immune cGAS-STING-TBK1 signaling pathway","volume":"10","author":"Ding","year":"2020","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.drudis.2021.06.010_b0285","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jaut.2018.02.001","article-title":"TBK1: a key regulator and potential treatment target for interferon positive Sjogren\u2019s syndrome, systemic lupus erythematosus and systemic sclerosis","volume":"91","author":"Bodewes","year":"2018","journal-title":"J Autoimmun"},{"key":"10.1016\/j.drudis.2021.06.010_b0290","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1093\/rheumatology\/kez508","article-title":"Inhibition of IFN\u03b1 secretion in cells from patients with juvenile dermatomyositis under TBK1 inhibitor treatment revealed by single-molecular assay technology","volume":"59","author":"Gitiaux","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.drudis.2021.06.010_b0295","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.4049\/jimmunol.1500162","article-title":"Cutting edge: inhibiting TBK1 by compound II ameliorates autoimmune disease in mice","volume":"195","author":"Hasan","year":"2015","journal-title":"J Immunol"},{"key":"10.1016\/j.drudis.2021.06.010_b0300","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nrrheum.2017.220","article-title":"Moving towards a molecular taxonomy of autoimmune diseases","volume":"14","author":"Barturen","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0305","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/art.41610","article-title":"Integrative analysis reveals a molecular stratification of systemic autoimmune diseases","volume":"73","author":"Barturen","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0310","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13075-017-1243-y","article-title":"Presence of an interferon signature in individuals who are anti-nuclear antibody positive lacking a systemic autoimmune rheumatic disease diagnosis","volume":"19","author":"Wither","year":"2017","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.drudis.2021.06.010_b0315","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1136\/annrheumdis-2018-213386","article-title":"Prediction of autoimmune connective tissue disease in an at-risk cohort: prognostic value of a novel two-score system for interferon status","volume":"77","author":"Md Yusof","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0320","doi-asserted-by":"crossref","DOI":"10.1136\/lupus-2014-000080","article-title":"Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE","volume":"2","author":"Kennedy","year":"2015","journal-title":"Lupus Sci Med"},{"key":"10.1016\/j.drudis.2021.06.010_b0325","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s12920-018-0468-1","article-title":"Association between changes in gene signatures expression and disease activity among patients with systemic lupus erythematosus","volume":"12","author":"Petri","year":"2019","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.drudis.2021.06.010_b0330","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1038\/s41598-018-24198-1","article-title":"A novel two-score system for interferon status segregates autoimmune diseases and correlates with clinical features","volume":"8","author":"El-Sherbiny","year":"2018","journal-title":"Sci Rep"},{"key":"10.1016\/j.drudis.2021.06.010_b0335","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1136\/annrheumdis-2019-215571","article-title":"Ultrasensitive serum interferon-\u03b1 quantification during SLE remission identifies patients at risk for relapse","volume":"78","author":"Mathian","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.drudis.2021.06.010_b0340","doi-asserted-by":"crossref","first-page":"3098","DOI":"10.1002\/art.24803","article-title":"Interferon-regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: a validation study","volume":"60","author":"Bauer","year":"2009","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.drudis.2021.06.010_b0345","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1002\/art.41187","article-title":"B cell tetherin: a flow cytometric cell-specific assay for response to type I interferon predicts clinical features and flares in systemic lupus erythematosus","volume":"72","author":"El-Sherbiny","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.drudis.2021.06.010_b0350","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2016-000292","article-title":"SIGLEC1 is a biomarker of disease activity and indicates extraglandular manifestation in primary Sj\u00f6gren\u2019s syndrome","volume":"2","author":"Rose","year":"2016","journal-title":"RMD Open"},{"key":"10.1016\/j.drudis.2021.06.010_b0355","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.cell.2016.03.008","article-title":"Personalized immunomonitoring uncovers molecular networks that stratify lupus patients","volume":"165","author":"Banchereau","year":"2016","journal-title":"Cell"}],"container-title":["Drug Discovery Today"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462100283X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S135964462100283X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T12:56:18Z","timestamp":1761224178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S135964462100283X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":71,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S135964462100283X"],"URL":"https:\/\/doi.org\/10.1016\/j.drudis.2021.06.010","relation":{},"ISSN":["1359-6446"],"issn-type":[{"value":"1359-6446","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"IFN-\u03b1: A key therapeutic target for multiple autoimmune rheumatic diseases","name":"articletitle","label":"Article Title"},{"value":"Drug Discovery Today","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.drudis.2021.06.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}